biostudies-literatureUnknown41(10)Isnardi CA<h4>Background/objective</h4>To evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) in Argentina: the SAR-CoVAC registry.<h4>Methods</h4>SAR-CoVAC is a national, multicenter, and observational registry. Adult patients with rheumatic or IMIDs vaccinated for SARS-CoV-2 were consecutively included between June 1 and September 17, 2021. Sociodemographic data, comorbidities, underlying rheumatic or IMIDs, treatments received, their modification prior to vaccination, and history of SARS-CoV-2 infection were recorded. In addition, date and place of vaccination, type of vaccine applied, scheme, adverse events (AE), disease flares, and new immune-mediated manifestations related to the vaccine were analyzed.<h4>Results</Clinical rheumatology3199-3209https://www.ebi.ac.uk/biostudies/studies/S-EPMC9244362biostudies-literatureAn Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.PMC9244362Isnardi CATissera YKogan NCosatti MAPisoni CNBertoli ALuna PCPons-Estel GJZelaya MDde Los Angeles Severina MAlonso CExeni MEDRetamozo CElkin MSGCosentino VCogo AKDe Los Angeles Correa MPereira DPetkovic ISchneeberger EERosemffet MMussano EEcheverria Cde la Vega MCQuintana RGarcia LKreimer JLLandi MNieto RESavio VGRoberts KVirasoro BMfalseAn Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.<h4>Background/objective</h4>To evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) in Argentina: the SAR-CoVAC registry.<h4>Methods</h4>SAR-CoVAC is a national, multicenter, and observational registry. Adult patients with rheumatic or IMIDs vaccinated for SARS-CoV-2 were consecutively included between June 1 and September 17, 2021. Sociodemographic data, comorbidities, underlying rheumatic or IMIDs, treatments received, their modification prior to vaccination, and history of SARS-CoV-2 infection were recorded. In addition, date and place of vaccination, type of vaccine applied, scheme, adverse events (AE), disease flares, and new immune-mediated manifestations related to the vaccine were analyzed.<h4>Results</2022-01-01T00:00:00Z2022 Oct2026-05-27T19:32:17.958Z2022-07-08T18:24:30.928ZS-EPMC92443623576093910.1007/s10067-022-06253-5